UnitedHealth Group stock is a top dividend growth stock with solid returns, reliable yield, and long-term growth prospects.

Shares of the healthcare giant are still down more than 30% year to date, after plunging as much as 53% at one point. Should ...

In recent months, UnitedHealth Group has raised premiums by around 20–30%, updated its 2025 earnings guidance, and faced ...

UnitedHealth Group has agreed to sell its last South American business Banmedica to Brazilian private equity group Patria ...

Mairs & Power, an investment advisor, released the third-quarter 2025 investor letter for the “Mairs & Power Balanced Fund.” A copy of the letter can be downloaded here. As we move into 2025, the ...

Discover why UnitedHealth Group (UNH) is rated Buy, with margin recovery, earnings growth, and 154% upside potential.

UnitedHealth Group, the company that owns healthcare conglomerate UnitedHealth, said on Thursday that it is cooperating with the federal government as it fields criminal and civil requests from ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. UnitedHealth Group profits fell to $3.4 billion in the second quarter as ...

UnitedHealth Group announced that it is under federal investigation looking into its Medicare Advantage (MA) plans, the privately run healthcare of the government’s Medicare coverage, typically for ...

UnitedHealth Group has reached a deal to sell its Latin American business Banmedica for $1 billion, according to media ...

Former UnitedHealth Group CEO William McGuire joins mediation team for Fairview and University of Minnesota merger negotiations.

UnitedHealth Group Inc. defeated an insurance reimbursement suit Tuesday after a federal appeals court affirmed the Employee ...